Alveus Therapeutics

About Alveus Therapeutics

Alveus Therapeutics is focused on redefining weight management by building a differentiated therapeutic portfolio that delivers sustainable weight loss with superior tolerability. Their mission is to improve patient outcomes and address the critical challenge of weight maintenance that limits current treatments.

Products & Services

ALV-100:Lead asset currently in Phase 2, focused on next-generation metabolic therapies for obesity.

Preclinical Amylin Pipeline:Consists of best-in-class peptides, oral small molecules, and other novel formats targeting improved quality of weight loss.

Specialties

Metabolic Disease Drug Development Obesity Treatment Next-Generation Metabolic Therapies Human Genetic Data Integration Clinical Expertise in Metabolic Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 197000000 MR: - FA: $197 million FAN: 197000000	D: 2026-02-24 FD: 2026-02-24	9 investors

Series A Latest

2026-02-24

$197.0M

9 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

N

Nayan Parekh

Chairman of the Board

R

Raj Kannan

CEO

J

Jacob Jeppesen

CSO and Head of R&D

X

Xiao-Ping Dai

Chief Technical Officer

B

Brian Bloomquist

Chief Business & Strategy Officer

C

Claudio Nessi

Board Member

View 9 more team members with Pro

Unlock Full Team Directory

Recent News